Literature DB >> 11221124

Vaginal yeasts in the era of "over the counter" antifungals.

P P Walker1, M T Reynolds, H R Ashbee, C Brown, E G Evans.   

Abstract

OBJECTIVE: To establish whether there has been any rise in the prevalence of non-albicans Candida species isolated from vaginal swabs since the introduction of "over the counter" antifungal treatments.
METHOD: A retrospective review looking at all positive vaginal yeast isolates collected from women attending one genitourinary medicine clinic during the 6 year period from 1993 to 1998 inclusive. All positive vaginal yeast isolates were included, regardless of whether or not the patients were symptomatic. Isolates from HIV positive women were excluded from the analysis.
RESULTS: No increase in non-albicans vaginal yeast isolates was shown during the period studied. The proportion of non-albicans yeasts remained constant at approximately 5% of the total yeasts isolated. The most common non-albicans yeast isolated was C glabrata.
CONCLUSION: There is no evidence from this study to suggest that the increasing use of "over the counter" antifungal treatment has selected for atypical, possibly inherently azole resistant, strains of vaginal yeasts in HIV seronegative women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11221124      PMCID: PMC1744236          DOI: 10.1136/sti.76.6.437

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  10 in total

1.  Women's use of over-the-counter antifungal medications for gynecologic symptoms.

Authors:  D G Ferris; C Dekle; M S Litaker
Journal:  J Fam Pract       Date:  1996-06       Impact factor: 0.493

2.  Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus.

Authors:  J D Sobel; J A Vazquez
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 4.  Vaginal infections in adult women.

Authors:  J D Sobel
Journal:  Med Clin North Am       Date:  1990-11       Impact factor: 5.456

5.  Prevalence of and risk factors for fungal vaginitis caused by non-albicans species.

Authors:  A Spinillo; E Capuzzo; R Gulminetti; P Marone; L Colonna; G Piazzi
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

6.  Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis.

Authors:  M E Lynch; J D Sobel; P L Fidel
Journal:  J Med Vet Mycol       Date:  1996 Sep-Oct

Review 7.  Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.

Authors:  J D Sobel
Journal:  Am J Obstet Gynecol       Date:  1985-08-01       Impact factor: 8.661

8.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period.

Authors:  M F Price; M T LaRocco; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

Authors:  J R Maenza; J C Keruly; R D Moore; R E Chaisson; W G Merz; J E Gallant
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

10.  Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

Authors:  M E Lynch; J D Sobel
Journal:  J Med Vet Mycol       Date:  1994
  10 in total
  8 in total

1.  Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013).

Authors:  W Mendling; K Friese; I Mylonas; E-R Weissenbacher; J Brasch; M Schaller; P Mayser; I Effendy; G Ginter-Hanselmayer; H Hof; O Cornely; M Ruhnke
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-04       Impact factor: 2.915

2.  An investigation into the pathogenesis of vulvo-vaginal candidosis.

Authors:  S S El-Din; M T Reynolds; H R Ashbee; R C Barton; E G Evans
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics.

Authors:  Marie V Pirotta; Suzanne M Garland
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

Review 4.  Treatment of sexually transmitted infections with single-dose therapy: a double-edged sword.

Authors:  Margaret Kingston; Elizabeth Carlin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Vulvovaginal Candidosis (Excluding Mucocutaneous Candidosis): Guideline of the German (DGGG), Austrian (OEGGG) and Swiss (SGGG) Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry Number 015/072, September 2020).

Authors:  Alex Farr; Isaak Effendy; Brigitte Frey Tirri; Herbert Hof; Peter Mayser; Ljubomir Petricevic; Markus Ruhnke; Martin Schaller; Axel P A Schäfer; Birgit Willinger; Werner Mendling
Journal:  Geburtshilfe Frauenheilkd       Date:  2021-04-14       Impact factor: 2.915

Review 6.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

8.  Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae.

Authors:  Seyed Ebrahim Hashemi; Tahereh Shokohi; Mahdi Abastabar; Narges Aslani; Mahbobeh Ghadamzadeh; Iman Haghani
Journal:  Curr Med Mycol       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.